In the Solodyn case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Medicis’s minocycline drug, Solodyn. The case alleges that Medicis engaged in an anticompetitive scheme to prevent lower-priced generic competition from entering the market. The scheme included product reformulations to prevent pharmacists from substituting less-expensive generic versions of Solodyn, and pay-for-delay conspiracies between Medicis and would-be generic competitors. The case settled for $75 million in early 2018.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 07/23/2013
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Neill W. Clark nclark@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771